AbCellera Biologics (ABCL) EBITDA: 2020-2023
Historic EBITDA for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$47.4 million.
- AbCellera Biologics' EBITDA fell 55.10% to -$47.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.7 million, marking a year-over-year decrease of 193.55%. This contributed to the annual value of -$165.5 million for FY2024, which is 12.80% down from last year.
- Latest data reveals that AbCellera Biologics reported EBITDA of -$47.4 million as of Q4 2023, which was down 68.29% from -$28.2 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' EBITDA ranged from a high of $169.1 million in Q1 2022 and a low of -$47.4 million during Q4 2023.
- Its 3-year average for EBITDA is $13.7 million, with a median of -$14.9 million in 2021.
- As far as peak fluctuations go, AbCellera Biologics' EBITDA soared by 5,624.08% in 2021, and later tumbled by 3,991.23% in 2022.
- AbCellera Biologics' EBITDA (Quarterly) stood at $117.0 million in 2020, then plummeted by 49.07% to $59.6 million in 2021, then tumbled by 151.30% to -$30.6 million in 2022, then plummeted by 55.10% to -$47.4 million in 2023.
- Its last three reported values are -$47.4 million in Q4 2023, -$28.2 million for Q3 2023, and -$30.4 million during Q2 2023.